Roivant Sciences ( (ROIV) ) just unveiled an announcement.
Roivant Sciences Ltd. reported promising results from Immunovant’s Phase 2a trial of batoclimab in treating Graves’ Disease, demonstrating significant response rates in patients not controlled by antithyroid drugs (ATDs). The drug achieved a 76% response rate at week 12, with a strong correlation between IgG reduction and clinical outcomes, suggesting a potential first-in-class and best-in-class treatment. With 25-30% of Graves’ Disease patients annually uncontrolled on ATDs and few therapeutic options, the commercial potential is substantial. A pivotal trial of IMVT-1402 is expected to commence by the end of the calendar year, following FDA alignment and IND clearance.
See more insights into ROIV stock on TipRanks’ Stock Analysis page.
